Table 2

Plasma tissue plasminogen activator (t-PA) antigen and activity in patients at baseline and during placebo and pravastatin treatment and in a matched control group

Patients
Substance P dose (pmol/min)ControlsBaselinePlaceboPravastatin
Data are mean (SEM). *p<0.001, one way analysis of variance in the infused forearm for each group.
t-PA antigen (ng/ml)
    Infused forearm*05.0 (0.5)4.6 (0.8)4.7 (0.6)4.5 (0.6)
25.6 (0.7)5.4 (0.8)5.4 (0.6)5.0 (0.4)
47.4 (0.8)5.7 (0.9)6.0 (0.9)5.8 (0.6)
88.0 (1.3)7.4 (1.1)7.5 (1.3)7.6 (1.1)
    Non-infused forearm04.7 (0.5)4.8 (0.7)4.5 (0.6)4.6 (0.6)
24.6 (0.4)4.8 (0.7)4.5 (0.5)4.5 (0.6)
45.8 (0.6)5.1 (0.8)4.5 (0.8)4.6 (0.6)
85.7 (0.6)5.0 (0.8)5.1 (0.6)4.8 (0.6)
t-PA activity (IU/ml)
    Infused forearm*00.6 (0.1)0.5 (0.1)0.6 (0.1)0.5 (0.1)
21.7 (0.5)1.3 (0.5)1.1 (0.4)1.6 (0.8)
42.7 (1.0)2.0 (0.6)1.7 (0.9)2.2 (1.1)
84.5 (1.5)3.4 (1.1)3.9 (1.4)3.1 (1.2)
    Non-infused forearm00.7 (0.1)0.4 (0.1)0.5 (0.1)0.4 (0.1)
20.8 (0.1)0.5 (0.1)0.6 (0.2)0.5 (0.1)
41.1 (0.2)0.6 (0.1)0.7 (0.2)0.6 (0.1)
81.7 (0.5)0.7 (0.2)0.8 (0.2)0.7 (0.2)